N-Acetylcysteine for Idiopathic Pulmonary Fibrosis: The Door Is Still Open

Lancet Respiratory Medicine,The - United Kingdom
doi 10.1016/s2213-2600(16)30327-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Open-Access Biorepository for Idiopathic Pulmonary Fibrosis. The Way Forward

Annals of the American Thoracic Society
PulmonaryRespiratory Medicine
2014English

Idiopathic Pulmonary Fibrosis: What Is the Best Treatment?

Barcelona Respiratory Network
2017English

Idiopathic Pulmonary Fibrosis

Pulmonologiya
PulmonaryRespiratory Medicine
2015English

Idiopathic Pulmonary Fibrosis

2020English

Diagnostic Criteria for Idiopathic Pulmonary Fibrosis

Lancet Respiratory Medicine,The
PulmonaryRespiratory Medicine
2018English

Triple Therapy for Idiopathic Pulmonary Fibrosis

Thorax
PulmonaryRespiratory Medicine
2012English

Emerging Drugs for Idiopathic Pulmonary Fibrosis

Expert Opinion on Emerging Drugs
Pharmacology
2011English

N‐acetylcysteine Is Unlikely to Reduce Hospitalisation for Chronic Obstructive Pulmonary Disease

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2003English

The Pathogenesis of Idiopathic Pulmonary Fibrosis

Therapeutic Advances in Respiratory Disease
PulmonaryRespiratory MedicinePharmacology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy